Calidi Biotherapeutics has a robust intellectual property portfolio around its proprietary cell-based carrier system designed to overcome the challenge of effective delivery of oncolytic viruses while providing better treatments with minimal toxicity and improved efficacy.  The portfolio consists of one allowed patent and over 14 patent applications worldwide.

Our patent strategy will continue to help Calidi Biotherapeutics expand and protect our cell-based delivery platforms as we grow and expand our product candidates. These patents represent the culmination of our research and hard work discovering how to potentiate oncolytic virus treatments for cancer.